Revive Therapeutics Ltd (RVVTF)

[Prominent Capital]

Pfizer's Oral Rheumatoid Arthritis

Treatment with Pfizer’s oral rheumatoid arthritis drug Xeljanz (tofacitinib) was associated with a reduction in death or respiratory failure in hospitalized patients with COVID-19-related pneumonia, according to findings from a study in Brazil. Findings from the placebo-controlled STOP-COVID study, published in the New England Journal of Medicine, suggest the oral Janus kinase (JAK) inhibitor tofacitinib could be a potential contender in the race to identify benefit for COVID-19 in already approved therapies. The therapy is currently approved for rheumatoid arthritis but not for COVID-19 or COVID-19-related pneumonia.


This article is talking for bucillamine and other drugs. Who’s gonna win among the competitors ?

https://www.biospace.com/article/covid-19-news-new-covid-19-vaccine-efficacy-mis-c-and-more-?fbclid=IwAR13cyKla5irxeeQcIvqqgnmvrYbDfUWCZ573Xc_TUtn8T6ZJ5dk__n1J4Q